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Medical devices are regulated in Europe by a new law from 26.5.2017 onwards. The name 
of the law is Medical Device Regulation (EU) 2017/745, MDR for short. The goal of this 
Master’s thesis was to provide the case company with recommendations on the actions that 
have to be taken to comply with the requirements set forth in the law, so that sales in Europe 
can continue when the transition period of the previous directive ends.  
 
The research was carried out by analysing the current state of the company; what had al-
ready been done for MDR. After this, recommendations were created for fulfilling the re-
quirements that still required actions. The recommendations were evaluated by 12 special-
ists working in the company, and they were updated based on these evaluations.  
 
The theory section of this thesis is a comprehensive information package on the new regu-
lation. It provides information about its effects on different stages of the approval process, 
for example quality management, risk management, incident reporting, UDI, and post-mar-
ket surveillance systems. In addition, the new requirement on the person responsible for 
regulatory compliance and the new European electronic database (Eudamed) are de-
scribed. The recommendations and their evaluation are described in the practical section. 
 
The actions taken based on the evaluated recommendations, which are the final results of 
this research will eventually be audited by a notified body. This may affect the recommen-
dations by making them even more comprehensive. However, the recommendations pre-
sented in this thesis are a good basis for fulfilling the requirements set forth in the new reg-
ulation. Because of the new law, fulfilling the requirements will be more time-consuming than 
before, and the need for documentation will increase. Special emphasis is given on the in-
creased requirements for the risk management system and clinical evaluations throughout 
the life cycle of the product.  
 
The Commission’s goal for the regulation is to remove the room for interpretation from the 
legislation, meet the challenges of developing technology, exclude problems that had oc-
curred in use, improve safety and people’s health and support the  functioning of the internal 
market while also maintaining the spirit of innovation. With the help of the recommendations, 
the case company can for their part help the Commission to reach this goal. 
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1 Introduction 
1.1 Background of Medical Device Legislation 
The development of legislation is often lagging behind, and this is the situation also in 
the case of medical devices. In the US, the regulation of such devices began in 1938 
when the FFDCA regulation (Device regulation under the federal food, drug, and cos-
metic act [1]) became effective. In Europe, each country had its own legislation until the 
European Union was formed and medical device directives [2] that bind all countries in 
the EU were created (Medical Device Directive (MDD) 93/42/EEC, Active Implantable Med-
ical Device (AIMD) 90/385/EEC, In Vitro Diagnostic Device (IVD), 98/79/EC). From the be-
ginning of the 1990s, each country applied these directives as a part of their own legis-
lation.  
 
However, it has been known for several years that the medical device directives need 
updating. The interpretation and application of the regulations in different countries 
caused differences of interpretation even between authorities, the technology used in 
the devices develops all the time, and the problems with the use of medical devices (such 
as the breast implant scandal in France that gained international attention in 2010) re-
quired that the requirements be checked and tightened. Therefore, two regulations based 
on the earlier directives were published in 2017 (the Medical Device Regulation (MDR) 
and the In Vitro Diagnostic Regulation (IVDR)), with transition periods of 3 and 5 years. 
The new regulations have to be taken into use in each member country as such, so they 
are no longer open to interpretation. The Commission’s additional goal for the regulations 
is to improve safety and health, and support the functioning of the internal market while 
maintaining the spirit of innovation.  
1.2 Current Challenges in Europe 
If a company wants to sell medical devices in Europe, the entire life cycle of the product 
(including design and manufacturing and the lifetime expectancy) has to comply with the 
current EU legislation for medical devices. During this research the transition period is 
ongoing in Europe, and two separate legislations are effective at the same time. In May 
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2020, the period of validity of the current regulation ends, and then, at the latest (in the-
ory, it is already possible) the companies that want to continue operating in the field  have 
to start operating in compliance with the requirements set forth in the new regulation 
(MDR), and to get an approval for their declaration of conformity from an external notified 
body, depending on the risk class, like has been done before with MDD. MDR will thus 
replace the current directive and national legislation as such.  
 
The current status of the notified bodies is problematic. In autumn 2017, guidelines were 
published regarding what is required from these bodies in the future concerning the reg-
ulation that became effective in spring 2017 (MDR). Because many of the currently MDD 
compliant notified bodies want to achieve MDR compliance as well, the submitted com-
pliance applications have piled up for the EU authority that approves the notified bodies. 
Because of this, there are no notified bodies in Finland, and not many elsewhere in the 
world, either, that are approved to operate as a notified body according to the new reg-
ulation (situation in April 2020). The earlier implications that these notified bodies would 
get their approval six months before the end of the transition period have not, for the 
most part, actualised, and the pressure that these bodies will have a massive amount of 
companies trying to get approval for their declarations of conformity within the set time 
limit grows all the time.  
 
In addition to the current lack of MDR compliant notified bodies there are also other chal-
lenges in the transition to MDR. The harmonised standards approved in the directive are 
not MDR approved yet, and the Eudamed database, which will be used to save infor-
mation about economic operators, notified bodies, certificates, unique device identifiers 
(UDI), serious incidents, clinical evaluations, and post-market surveillance, is not in use.  
 
Originally the regulation was planned to be effective on 26.5.2020 (Date of Application, 
DoA), but now the deadline will probably be delayed by a year till May 2021. The require-
ments set forth in the new regulation and the incomplete structures in relation to its tight 
schedule are a big challenge to European authorities and notified bodies, as well as to 
economic operators.  
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1.3 Transition from legislation to another as a company level 
The case company (founded in the 1970s) designs, manufactures, and markets medical 
devices for dentistry in Herttoniemi, Helsinki. The main market area for the company is 
Europe, but the products are exported all over the world. The company has a valid MDD 
certificate, which certifies that the operations comply with European legislation. Thus, the 
products can be marked with a CE mark at the moment (situation in April 2020). How-
ever, this certificate will expire eventually, and it cannot be renewed anymore in accord-
ance with the MDD. In order the business operations can continue in Europe and also in 
several other countries where EU approval is used fully or in part to achieve marketing 
authorization, some activities have to be updated or modified to comply with the new 
regulation. Because of this, the company has ordered this research to identify and adopt 
the new obligations. As a result of this research, the company is provided with recom-
mendations on how the requirements set forth in the regulation are to be implemented, 
which will contribute to making it possible to continue business operations in Europe and 
globally.  
1.4 Scope 
The topic of this research is the new European legislation for medical devices: Medical 
Device Regulation (EU) 2017/745, MDR in short. The research is thus limited in accord-
ance with the regulation to medical devices only, excluding in vitro devices, which have 
a separate regulation (Regulation on in vitro diagnostic medical devices (EU) 2017/746). 
The regulation defines medical device as any device, instrument, or software intended 
by the manufacturer to be used for human beings for medical purposes, such as diagno-
sis or treatment of disease or injury or investigation of a physiological state.  
 
Considering the case company’s role in the market and its product portfolio, there are 
several limits set for the research to concentrate on for example mass-produced and its 
current risk class devices which have been manufactured in Europe. Table 1 (below) lists 
the contents of this research, and also what has been left out.  
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Table 1: Contents and exclusion criterias of the research 
 
Contents of the research Not included in this research 
Medical devices  In vitro devices  
Manufacturer obligations  
The obligations of importer, distributor, and 
authorised representative (AR) 
Products manufactured in Europe  Products manufactured outside Europe  
Mass-produced devices  Custom-made devices  
Risk class I, Im, IIa and IIb devices  Risk class III devices  
Conformity assessment method based on qual-
ity management system and the evaluation of 
technical documents  
Conformity assessment method based on 
type examination  
Non-sterile devices  Sterile devices  
Devices currently in the market  New devices  
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2 Medical Device Regulation (MDR) 
 
The first purpose of this Master’s thesis is to give an overall idea of what obligations the 
new regulation determines. The expiring MDD directive (93/42/EEC) and the new MDR 
regulation (2017/745) contain mostly the same basic requirements for manufacturers 
and products. The number of old requirements has not decreased, but new requirements 
have been added.  
 
Because the new MDR has over 20 articles that bind the manufacturer, and more than 
10 applicable annexes, the content is limited to the parts that are the most relevant for 
the case company. They address the other goal of this thesis – provide the case com-
pany with recommendations on actions to be taken to comply with the requirements set 
forth in the regulation.  
2.1 Definitions and Scope  
The notification drawn up by the Union, Factsheet for Manufacturers of Medical Devices 
[3], describes how the definitions have slightly changed when moving from the directive 
to the regulation. To ensure shared understanding at the EU level, 57 new definitions for 
terms have been added to the regulation. Some of the main examples of these new 
definitions are Unique Device Identifier (chapter 2.2.9), Clinical Data (chapter 2.3), Clin-
ical Evidence (chapter 2.3) and Serious Incident (chapter 2.4.2), all of them are explained 
more in the chapters listed after definitions.   
 
The scope of Medical Device Regulation follows basically the same lines as the current 
directive MDD. Regulation [4] says: “Regulation lays down rules concerning the placing 
on the market, making available on the market or putting into service of medical devices 
for human use and accessories for such devices in the Union.” There are still some ex-
tensions in MDR, which shall be taken into the consideration when determining, if the 
device fall in the scope of regulation.  
 
The first example is, as Emergo, a company specialising on international consulting, 
writes in their notification Understanding Europe’s New Medical Devices Regulation [5], 
that the new regulation will place requirements also on some devices that do not have a 
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medical purpose. One example of this kind of products is contact lenses. Another exam-
ple is described in the Commission’s instructions Factsheet for Manufacturers [3]: “Soft-
ware, which have medical purpose, whether embedded or not, falls within the scope of 
MDR.” Previously this kind of software were mostly non-medical devices. Third example 
are the devices for cleaning, disinfection or the sterilization of devices, which will now be 
considered as medical devices, whereas before they were only accessories to medical 
devices, says Petri Pommelin, former Finnish competent authority (1992-2006), in his 
book Survival Guide to EU Medical Device Regulations [6].  
2.2 General Obligations for Manufacturers 
The new regulation lists several different obligations and recommendations for manufac-
turers throughout the life cycle of the device. The most essential ones are explained 
below. Clinical compliance (chapter 2.3) and post-market surveillance (chapter 2.4) are 
separated into sub-chapters because of their extensive content.  
 
2.2.1 Person Responsible for Regulatory Compliance (PRRC) 
 
One of the new requirements of the regulation is that the manufacturer has to have in 
their organisation permanently (midsize and large companies) or continuously available 
(micro and small companies) at least one person responsible for regulatory compliance 
(PRRC). If there are more than one person, the division of responsibilities has to be 
defined in a written form. The person must be formally qualified for the task. The qualifi-
cation is attained either through an appropriate university degree and one year of work 
experience, or by four years of work experience about regulatory affairs related to med-
ical devices or quality management systems. The person has to be registered in Eu-
damed (when available). In addition, it has been defined that the person must not be 
legally in weaker position within the organisation because he or she is performing the 
duties. In Finland, health technology, including PRRC, is supervised by Fimea (Finnish 
Medicines Agency).  
 
PRRC is responsible, for example, for making sure that product conformity is assessed 
appropriately before the device is placed in the market, technical documents and decla-
ration of conformities (DoC) are drawn up and kept up to date, post-market surveillance 
obligations are fulfilled, and authorities and, depending on the device, the notified body 
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and partners in the target country (economic operators) are informed and the necessary 
notifications are given. COCIR (European coordination committee of the radiological, 
electromedical and healthcare IT industry) recommends limiting the person’s liability with 
an agreement between the person and the company. In addition, they recommend that 
the responsible person takes a personal liability insurance for possible legal conse-
quences [7].  
 
2.2.2 Classification of Devices 
 
The classification of medical devices into different risk classes is already used in the 
expiring directive. The new regulation does not bring significant changes to this. The 
classes (I, IIa, IIb and III) stay the same, and devices are still placed in the classes based 
on their purpose of use and typical risks. However, noteworthy changes are the new 
rules 9 for nanomaterials and 11 for software programs, which elevate them to medical 
devices. The guidance document on the classification of medical devices “MEDDEV 2.4” 
[8] is still a very useful document according to Petri Pommelin [6] when the manufacturer 
analyses the classification of their products. The notified body and the Competent Au-
thorities for Medical Devices (CAMD) in a European manufacturing country help with the 
classification if needed.  
 
The case company’s devices will probably stay in their current classes (I, Im, IIa and IIb), 
with the elaboration that the situation of software has to be re-evaluated because of the 
adoption of MDR. The product range of the company in question does not include nano-
materials or products that contain them.  
 
2.2.3 Conformity Assessment Procedures 
 
The conformity assessment procedure in the Union depends on the risk class of the 
device both in the current directive and in the new regulation. The case company’s prod-
ucts are currently in risk classes I, Im, IIa, and IIb, and the assumption is that this will not 
change, so the focus in this chapter is on the assessment procedures of these classes. 
For the company’s current devices, the directive-compliant approval is based on the 
quality system (93/42/EEC Annex II, Excluding Section 4), and the plan is to continue 
using it, as applicable, even after the new regulation becomes effective. In the regulation, 
the selected route is called “Conformity assessment based on a quality management 
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system and on assessment of technical documentation” (Annex IX). There are several, 
risk class depending stages in the approval process, depicted in picture 1. 
 
  
Picture 1: Medical Device MDR CE Marking Process [9] 
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When a device, for which an application for EU approval is planned, has been identified, 
its risk class is determined. There are specific classification rules for this purpose in the 
regulation. For devices in the lower risk class (class I), it is enough in the future if they 
have a technical file and a declaration of conformity. For devices in higher risk classes, 
the use of a notified body, the existence of a quality system, and more specific post-
market surveillance are required. The approval requirements of the regulation by risk 
class are presented in table 2 below.  
 
Table 2: Requirements for risk classes  
 
  TDA PMS DoC NB QMS PSUR 
Class I X X X       
Class Im X X X X X   
Class IIa X X X X X X 
Class IIb X X X X X X 
 
TDA  = Technical Documentation Assessment 
PMS  = Post Market Surveillance 
DoC  = Declaration of Conformity 
NB   = Notified Body 
QMS  = Quality Management System 
PSUR = Periodic Safety Update Report 
 
The presence of the notified body in the conformity assessment procedure will continue 
as it is now: it is obligatory for class Im, IIa, and IIb devices. The case company will 
probably continue cooperation with the current notified body, assuming that it gets the 
MDR qualification it has applied for.  
 
The case company has many devices approved for the European market according to 
the current directive. The adoption of the regulation brings about the following changes:  
• The device approvals compliant with the directive are valid until 26.5.2024 at the 
most, if significant changes are not made to them, after which they expire auto-
matically. The validity requires MDD compliant yearly follow-up audits.  
• After 26.5.2020 it is not possible to apply for an MDD approval anymore, and 
therefore only MDR approvals are possible from that date onward (if there is an 
MDR-approved notified body then).  
 
In practice, this means that if an MDD approval expires between May 2020 and May 
2024, an MDR approval has to be applied for the device if the company wants to continue 
selling it. If major changes are made to the product after May 2020, an MDR approval 
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has to be applied for it. There is a need for MDR approval in 2024 the latest. It is, of 
course, possible to prune the current product portfolio, in which case the approvals will 
expire and the marketing authorizations cease on their own. If possible, it is recom-
mended to already apply for MDR-compliant approvals for new devices, so that the even-
tual reapproval process will be easier.  
 
2.2.4 Harmonized Standards   
 
The Finnish Standards Association (SFS) summarises the definition of a standard as 
follows [10]: A standard is a shared procedure for repeated actions. Standards are rec-
ommendations by nature, but authorities may require that they be used. A standard is a 
written publication, and it is approved by an authority, organization, or other recognized 
body that is responsible for standardization. In order to make the manufacturing of reg-
ulation-compliant devices easier, the EU requests European organizations of standardi-
zation to draw up detailed standards to expand on directives and regulations. They are 
given an official status as additions to directives by mentioning them in the Official Jour-
nal of the European Union (OJEU). Standards retain their voluntary nature, but the prod-
ucts that fulfil the requirements of the standards are deemed to fulfil the requirements of 
the regulations insofar as they concern things in essential requirements.   
 
Standards that acquire an official status are called harmonised standards in the Euro-
pean Union. Manufacturers and other operators are thus free to use standards or choose 
some other technical solution to show compliance with obligatory legal requirements. 
However, the use of standards makes it easier to demonstrate conformity to authorities 
in different countries, because their requirements are known to everybody.  
 
The expiring directive is associated with several harmonized standards. A similar list of 
harmonised standards for MDR has not been published yet. There is, however, a draft 
version of such list [11], which implies that there is a future for the familiar standards, 
and it is probably a good idea for manufacturers to continue using them until they are 
made official, in other words published in the Official Journal. For example, the quality 
system (ISO 13485) and risk management system (ISO 14971), also mentioned in the 
regulation, both have their own standards and are included in the draft list mentioned 
above.  
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2.2.5 Risk Management System 
 
The manufacturer of medical devices has to set up, document, implement, and maintain 
a risk management system. Risk management is a repeating process, and it has to be 
updated regularly and systematically. MDR brings about some special considerations to 
risk management: ”In carrying out risk management, manufacturers shall … evaluate the 
impact of information … , in particular, from the post-market surveillance system, on 
hazards and the frequency of occurrence thereof, on estimates of their associated risks, 
as well as on the overall risk, benefit-risk ratio and risk acceptability.” [4] 
 
The case company already uses a risk management tool: ISO 14971 - Medical devices 
-- Application of risk management to medical devices [12], which is also listed in the MDR 
draft of the harmonized standards [11], so it seems that its use will continue in the same 
way as before. Picture 2 illustrates the risk management process from the point of view 
of the ISO 14971 standard. 
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Picture 2: A schematic presentation of the risk management process [12] 
 
The risk management system contains risk analysis and the risk management section. 
The analysis considers the risks, and the management attempts to remove or minimize 
them. Because it is not possible to remove all risks, a decision has to be made on ac-
cepting residual risks in relation to the benefits the device produces. Therefore, the ex-
pression “benefit-risk analysis” is often used. Risk management covers the entire life 
cycle of the product, from the beginning of design to the time when sales have ended. 
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Risk analysis has to be maintained and updated actively based on feedback from dif-
ferent sources. Such sources include, for example, the manufacturer’s own observa-
tions and PMS, as well as trend follow-up.  
 
2.2.6 Quality Management System (QMS)  
 
The manufacturer has to set up, document, implement, and maintain a quality manage-
ment system. The case company already has certified a harmonised standard ISO 
13485 - Medical devices -- Quality management systems -- Requirements for regula-
tory purposes [13], which has been approved in the directive. There are grounds for 
continuing to use and certify it, because it is already included in the draft list of harmo-
nised standards for MDR, and because the case company wants to continue to get ap-
provals for their devices in the method based on the quality system. Picture 3 is a com-
prehensive presentation of the requirements of the newest standard version.   
 
 
Picture 3: Requirements, clauses and sub-clauses of the standard ISO 13485 v 2016 
[14] 
 
A quality management system, like the one in picture 3, is a management system whose 
purpose is to fulfil the clients’ requirements and attempt to exceed customer expecta-
tions. With the help of the system, management is able to reach its goals, people are 
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fully involved, the operations follow processes and it is possible improve them, decision-
making is based on evidence and managing the relationships with interest groups brings 
about continuous success. A quality system that follows ISO 13485 gives instructions for 
the whole life cycle of the product. There are obligations for company management, 
product design, and manufacturing, but documentation and customer deliveries are not 
forgotten, either. The commission has attempted to keep the regulation consistent with 
the quality standard for medical devices when creating the MDR regulation.  
 
2.2.7 Technical File 
 
The manufacturer has to create a technical file of the documents of its medical devices 
and keep it up to date. The technical documents have to be sufficient for the regulation’s 
conformity assessment. The content of the file is depicted in picture 4, and for example 
the following topics have to be found:  
• Description and specification of the device, including variants and accessories  
• Information provided by the manufacturer  
• Design and manufacturing information  
• General safety and performace requirements  
• Benefit-risk analysis and risk management  
• Product verification and validation  
 
Picture 4: Subsets of Technical Documentation [15] 
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Thus, the file consists of documents from the design phase (Design History File), pro-
duced by manufacturing (Device Master Record), and post-market documents, comple-
mented with content from the quality system (QMS). The summary of the technical file is 
called STED (Summary of Technical Documentation). The manufacturer has to keep the 
technical documents of the device for the whole life cycle of the product and 10 years 
after the end of its sales. The file or its summary has to be provided to the competent 
authority if requested.  
 
2.2.8 European Database (Eudamed) 
 
The Commission sets up, maintains, and administers the European database on medical 
devices called Eudamed. The goal is to increase visibility and the availability of infor-
mation on medical devices. In the future, the registered economic operators and devices 
with their approvals and identifiers, incidents, post-market surveillance, and clinical eval-
uations, for example, can be found in the system. Picture 5 (below) depicts the division 
of Eudamed into different sections.  
 
 
 
Picture 5: Eudamed’s structure [16] 
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Some parts of the system will be open to everyone (e.g. devices in the market and eco-
nomic operators), while others can only be viewed by certain operators. This is presented 
in picture 5 with rectangulars of different colours. All information is available to the Com-
mission and the competent authorities. Eudamed is free of charge to the users.  
 
The regulation obligates economic operators to save a lot of different kinds of information 
to Eudamed. Anu Lehtonen writes in her thesis EU:n asetus lääkinnällisistä laitteista 
(MDR) (The European Union’s regulation on medical devices (MDR)) [17] that the man-
ufacturer can choose whether they want to provide the information manually, using XML 
download or M2M technology. Each option has its own challenges. The manual method 
requires instructions for use, in XML downloading the data has to be EC compatible, and 
M2M requires a system based on AS4 protocol, so that the data can be transferred di-
rectly from the manufacturer to the database. The Guidelines for Member States on the 
use of Data Exchange solutions [18], created by the Union, helps to get more information 
on this.  
 
The database has not been published yet (situation in April 2020). The regulation esti-
mates that it will be in use by the time the transition period ends in May 2020, but the 
possible postponement is already taken into account in the regulation. It was mentioned 
in the Regulatory & Compliance Summit Conference in February 2020 that Eudamed is 
not expected to be ready until Q2/2022 [19]. Economic operators are therefore recom-
mended to follow the Commission’s notifications regarding the adoption of Eudamed.  
 
2.2.9 Unique Device Identification (UDI) 
 
The identification and traceability requirements of devices will expand in Europe because 
of the new regulation. To make managing them easier, the regulation requires that a 
unique device identification, UDI system, is taken into use. For those manufacturers that 
currently export products to the USA, this requirement is already quite familiar from the 
UDI by Food and Drug Administration (FDA).  
 
UDI is formed from UDI-DI, device-group-specific identifier (the approved issuing entities 
provide the information), and UDI-PI, device-specific identifier such as serial number. 
The way UDI is formed is presented in more detail in the picture 6 (below). 
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Picture 6: Terms of UDI [20] 
 
According to the regulation, the UDI system has to be applied to all medical devices 
placed in the market, except for custom-made devices. To fulfil the requirements, the 
manufacturers have to  
• produce the UDI-DI part (picture 6) needed for the UDI code, using the issuing 
entities approved by the Commission: GS1 AISBL, Health Industry Business 
Communications Council (HIBCC), International Council for Commonality in 
Blood Banking, Automation (ICCBBA), Informationsstelle für Arzneispezialitäten 
(IFA) Gmb [21] 
• publish the UDI in the Eudamed database  
• place the UDI identifier (human readable interpretation (HRI) and barcode) in the 
product and/or package  
• use the UDI when reporting serious incidents and field safety corrective actions  
• mark the UDI-DI in the declaration of conformity (DoC)  
• keep an up-to-date list of all the UDI devices the manufacturer has named as a 
part of the technical documentation. 
 
The UDI information has to be saved in the UDI database (Eudamed) by 26 November 
2021 (if Eudamed is working). The UDI has to be marked in the product or package by 
26 May 2023 (class IIa and IIb devices) and 26 May 2025 (class I devices).  
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2.2.10 Labeling 
 
The regulation defines the minimum amount of information the manufacturer has to pro-
vide in their customer documents that are supplied with the device. The information has 
to be provided in the Union’s official language or official languages, defined by the mem-
ber country where the device will be placed available to users or patients. The infor-
mation included in the label has to be permanent, easily readable, and clearly under-
standable for the intended user or patient. The requirements set forth in the directive will 
stay as they are, and as a new requirement the unique device identifier UDI (chapter 
2.2.9) will be added to customer documents.  
 
2.2.11 Declaration of Conformity (DoC) 
 
The EU Declaration of Conformity is a document, in which the manufacturer declares 
that the product conforms to the requirements. The EU Declaration of Conformity is a 
part of the conformity assessment procedure in accordance with the EU product legisla-
tion, writes The Finnish Safety and Chemicals Agency Tukes on their website [22]. The 
manufacturer has to draw up a DoC before the product is placed on the market, and it 
has to be translated into one of Union’s official languages or into the language(s) which 
the member countries require. For each device there can be only one DoC, which shows 
all the Union’s regulations that are applied to the device, was told in the SGS Academy 
seminar in 2018 [23].  
 
A DoC that has been updated to be MDR compliant contains everything the directive 
requires, and also: 
• the registration number of the company (when Eudamed is working)  
• unique UDI-DI identifier (when in use)  
• the intended use of the device  
• MDD conformity updated to MDR conformity  
• as applicable, the number of the certificate issued by the notified body.  
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2.2.12 Certificate of Free Sale (FSC) 
 
The certificate of free sale is a familiar document already from the directive’s time. It is 
issued upon manufacturer’s request for export, for CE-marked devices that are sold in 
the Union. In Finland, it is issued by Fimea. One of the new requirements is to supple-
ment it with a part of the device identifier, the so-called Basic UDI-DI (chapter 2.2.9), and 
the number of the certificate issued by the notified body, if it exists.  
 
2.2.13 Identification within the Supply Chain 
 
The identification requirements within the supply chain expand because of the new reg-
ulation. According to the regulation, economic operators, such as the manufacturer and 
distributors, have to be able to identify and, if requested, deliver to the competent au-
thority the information about where they got the device and to whom they have delivered 
it. Importers and distributors are obligated to collaborate more closely with the manufac-
turer to ensure appropriate identification for 10 years. The UDI system (2.2.9) helps to 
manage this requirement.  
2.3 Clinical Compliance 
Patient safety and the performance of the device are the essential requirements of a 
medical device. As a part of the approval process, devices are tested based on harmo-
nised safety standards, but in the legislation there are also requirements for tests carried 
out in authentic environments of use, called clinical tests.  
 
With MDR, the requirement for clinical evaluations and investigations is further high-
lighted, new ways of working are adopted, and they are expanded to cover devices in 
more risk classes than before. The process, which covers the whole life cycle of the 
product, is presented in picture 7 below.  
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Picture 7: Clinical evaluation process [24] 
 
The evaluation and investigation of clinical safety are divided, as depicted in picture 7, 
into time before placing the device in the market (orange boxes) and after placing the 
device in the market (other boxes). Before placing the device in the market, a clinical 
evaluation and investigations, taking into account the risk class, are carried out for the 
device, and these result is the Clinical Evaluation Report (CER), which is a part of the 
technical file of the device. Post-market actions (described in more detail in chapter 2.4) 
include, as described in the process description presented above, the PMS plan, Post-
Market Clinical Follow-Up (PMCF), incident monitoring, and PSUR, which all have to be 
used as sources of information for updating the CER during the life cycle of the product. 
In the following sub-chapters, the requirements of clinical evaluation and investigation 
are described in more detail.  
 
2.3.1 Clinical Evaluation 
 
The regulation defines clinical evaluation as a systematic and planned process carried 
out by the manufacturer, whereby the safety and performance of the device in its in-
tended purpose of use, including clinical benefits, is continuously produced, collected, 
analysed, and evaluated. The clinical evaluation starts with the clinical evaluation plan. 
In the plan, the manufacturer has to specify and justify the level of clinical evidence which 
is needed to demonstrate compliance with the relevant general safety and performance 
requirements. This level has to be appropriate considering the features of the device and 
its intended use.  
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After the plan, a clinical evaluation is carried out, based on literature and existing infor-
mation. It has to be documented. The evaluation has to be a thorough and objective 
review of the current state, which takes into account both favourable and unfavourable 
information. It is recommended to use the instruction MEDDEV 2.7/1: Clinical Evaluation 
[25], from the time of the directive, in the evaluation process.  
 
2.3.2 Clinical Investigations 
 
A clinical investigation is defined in the regulation as a systematic research, which in-
volves one or more people to be studied, and the purpose of which is to evaluate the 
safety and performance of the investigated device. During the directive, just a clinical 
evaluation (chapter 2.3.1) was often sufficient clinical evidence, in other words, a litera-
ture review by comparing with other similar devices. Now this method option has been 
limited in the regulation. Based on this, it can be said that clinical investigation can in 
many cases be considered as a new requirement.  
 
To avoid performing a clinical investigation, the manufacturer can use the clinical inves-
tigation of a similar device that is already in the market, if both manufacturers have a 
valid agreement based on which the manufacturer of the other device grants full and 
continuous access to their technical documents. In addition, it is required that the original 
clinical evaluation has been carried out in accordance with the requirements, and the 
manufacturer of the other device provides clear evidence of that to the notified body.  
 
If the procedure of using clinical investigation of a similar device is not possible, the 
manufacturer has to commission an investigation. The clinical investigation is made eas-
ier by the fact that in the future, a unified standard for clinical investigations ISO 14155 - 
Clinical investigation of medical devices for human subjects -- Good clinical practice [26], 
will probably be made official, because it is already mentioned in the draft list of harmo-
nized standards [11]. In addition, it is recommended to take into account the guidelines 
that were approved in the directive’s time, MEDDEV 2.7/4: Guidelines on Clinical Inves-
tigation [27], which gives important information on the matter. The manufacturer of risk 
class IIb devices can hear a panel of specialists appointed by the Union before the clin-
ical investigation to specify the clinical development strategy of the plan and recommen-
dations of the clinical research, the regulation states.  
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Clinical investigations have to be planned, approved, performed, recorded and reported 
when they are carried out for conformity assessment. The investigation has to:  
• ensure that the device is designed, manufactured, and packed so that it is appro-
priate for the special uses listed in the regulation and it reaches the performance 
defined by the manufacturer  
• analyse and check the clinical benefits of the device defined by the manufacturer  
• ensure the clinical safety of the device and define the possible unwanted side 
effects in the normal environments of use, and assess if they form acceptable 
risks, taking into account the benefits of the device.  
 
A permission has to be obtained from the Commission for performing a clinical investi-
gation. The regulation instructs the sponsor of the investigation to supply the application 
documents to the member country/countries where the clinical investigation is planned 
to be carried out. The application is submitted in Eudamed (when available), which gives 
the clinical investigation a union-wide unique identification number that is used in all 
communication related to the clinical investigation. The member country in question has 
to inform the sponsor in 10 days after receiving the application whether the clinical in-
vestigation is in the scope of this regulation and whether the application document is 
complete. For the devices in the risk classes of the case company, the clinical investiga-
tion can usually be started right after getting the confirmation from the member country.  
 
The regulation lists the following general obligations for performing clinical investigations:  
• The party who commissions the investigation (the sponsor) and the investigator 
have to ensure that the clinical investigation is carried out according to the ac-
cepted clinical investigation plan. 
• The sponsor has to ensure that the rights, safety, and well-being of the research 
subjects are secured, that the provided information is reliable and the research 
to be carried out is compliant with the requirements set forth in the regulation. In 
addition, the sponsor has to ensure sufficient surveillance for the investigation. 
• The sponsor and the investigator have to save, modify, handle, and keep all the 
information pertaining to the clinical trial in such manner that they can be com-
municated in detail, interpreted and verified while maintaining the confidentiality 
of the documents and the personal information of the research subjects.  
• The sponsor has to create a process for emergencies, which makes it possible 
to immediately identify the devices used in the investigation, and if necessary, 
recall them.  
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2.4 Post-Market Surveillance System 
 
2.4.1 Post-Market Surveillance (PMS) 
 
Nowadays the life cycle of a product is thought to expand beyond the time the product is 
for sale. The life cycle is considered to start from the beginning of design, and end 10 
years after the product is discontinued. The MDR has expanded obligations also for the 
time after the product is taken into use.  
 
The manufacturer has to plan, draw up, document, carry out, maintain, and update a 
post-market surveillance system (plans and reports) for each device, proportionate to the 
risk class and in a way suitable for the device type. The PMS has to be an integrated 
part of the manufacturer’s quality system, says Petri Pommelin [6]. This is carried out by, 
for example, creating a standard operating procedure about it that belongs to the quality 
system. The PMS system is divided into parts and described in detail below. Picture 8 
illustrates the reporting obligations.  
 
 
 
Picture 8: Post-Market Surveillance Activities [28]  
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The manufacturer has to have a PMS system, based on the PMS plan. The plan shows 
how information is collected (e.g. vigilance, feedbacks, post-market clinical follow-up), 
analysed (CAPA), and reported (Eudamed) in the way required by the risk class of the 
device, and what the information is used for:  
• developing and improving risk management  
• updating design and manufacturing information and customer documents  
• updating the clinical evaluation  
• identifying the need for preventive, corrective, or field safety corrective actions  
• identifying the improvement possibilities of usability, performance, and safety  
• the contribution of the post-market surveillance of other devices and trend obser-
vation and reporting (as applicable). 
 
The reports that are drawn up based on the plan are different, and different requirements 
concern them, depending on the risk class of the device. The different report types are 
presented next.  
Post-Market Surveillance Report for class I devices 
 
The manufacturer has to draw up a post-market surveillance report, which presents a 
summary of the results of post-market surveillance analysis and conclusions, as well as 
grounds for and description of all preventive and corrective actions. The report is updated 
when necessary and made available to a competent authority if requested.  
 
Periodic Safety Update Report (PSUR) for class IIa and IIb devices 
 
The manufacturer has to draw up a periodic safety update report for a device or a device 
group which presents a summary of the post-market surveillance analysis and conclu-
sions, as well as grounds for and description of possible preventive and corrective ac-
tions. The lifelong PSUR has to present:  
• conclusions of the risk analysis  
• main findings of PMCF  
• the sales volume of the device and estimated size of the population using the 
device and other features and, if possible, the frequency of use of the device.  
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For class IIa devices, the manufacturers have to update safety reports when necessary, 
and at least every two years. For class IIb devices, the PSUR has to be updated every 
year.  
 
2.4.2 Serious Incidents and Field Safety Corrective Actions 
 
The current directive already requires the manufacturer to inform competent authorities 
of suspected incidents and need for field safety corrective actions. A new requirement 
brought by the regulation is that this information has to be delivered through Eudamed 
(2.2.8), and the notified body has to be informed as well (as applicable) of non-conformity 
and possible corrective actions.  
 
The manufacturers have to deliver, upon the request of competent authority, all infor-
mation and documents that are needed to demonstrate conformity of the device in the 
union’s official language defined by the concerned member state. The competent au-
thority of the member country where the manufacturer has a registered place of business 
may require the manufacturer to deliver samples of the device free of charge, or if that 
is not possible in practice, to grant permission to use the device. Manufacturers have to 
work in cooperation with the competent authority upon its request in all corrective actions 
that are carried out to remove risks caused by placing the device in the market or taking 
the device into use, or if that is not possible, to decrease them.  
 
A manufacturer that believes or has a reason to suspect that the device placed in the 
market is not compliant with the MDR has to immediately take the necessary corrective 
actions to make the device compliant or to remove it from the market. The manufac-
turer has to inform the device distributors about this, says the regulation.  
 
Natural persons or legal persons can claim compensation for damage caused by a faulty 
device according to the applicable legislation of the union or national legislation. Accord-
ing to the regulation, the manufacturers must have defined actions in proportion to the 
risk class, device type and the size of the business that ensure sufficient funds for their 
possible responsibility in accordance with the directive 85/374/ETY.  
 
Manufacturers must have a system for recording and reporting incidents and field safety 
corrective actions. MEDDEV 2.12: Guidelines on a Medical Devices Vigilance System 
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[29], approved as official instructions during the directive’s time, helps in creating and 
maintaining the system. According to the regulation, analysing serious incidents and field 
safety corrective actions are the manufacturer’s responsibility as follows: 
• notification obligation to authority/notified body, distributor, etc.  
• necessary investigations carried out without delay for serious incidents and the 
devices in question  
• cooperation with authority and notified body during the investigations  
• final report with conclusions and possible corrective actions to authority through 
Eudamed.  
 
According to the regulation, the manufacturer has to make sure that the users of the 
device in question are immediately informed about field safety corrective actions that 
have been taken by a safety notification. The notification has to be delivered in the un-
ion’s official language or languages, defined by the member country where the field 
safety corrective actions are taken. Except for urgent cases, the content of the safety 
notification draft has to be delivered to the competent authority so that they can comment 
on it if necessary.  
 
The device or devices and the manufacturer that carried out the field safety corrective 
action have to be appropriately identifiable based on the safety notification. This is ac-
complished by, for example, including the unique UDI-DI identifier of the device and the 
manufacturer’s registration number in the notification. The notification has to describe 
the reasons for the field safety corrective action clearly and without belittling the risk level 
by referring to the malfunctioning of the device and the risks for patients, users, and other 
people. In addition, it has to list clearly all actions the users have to take. The manufac-
turer has to save the safety notification in Eudamed (chapter 2.2.8), through which it is 
made available to the general public, the regulation says.  
 
2.4.3 Trend Reporting 
 
MDR adds a new requirement to complement the requirements on serious incidents and 
field safety corrective actions, the requirement of trend follow-up. In the future, the man-
ufacturer has to follow and report statistically significant increases in the frequency or 
severity of side effects that could have a significant effect on benefit-risk analysis and 
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that have caused or could cause, in proportion with the benefits, unacceptable risks for 
the health or safety of patients, users or other people. A significant increase means an 
increase in the frequency or severity of the foreseeable side effects in a particular time 
period defined in the technical file.  
 
The manufacturer has to define a process that is followed to observe statistically signifi-
cant increases and the frequency of the observation periods. In the future, trend reporting 
will be carried out through Eudamed (when available).  
2.5 Notified Bodies 
A notified body is an organisation which an EU member country has named to assess 
the conformity of particular products before they are placed in the market. These bodies 
carry out the tasks pertaining to the conformity assessment procedures confirmed in the 
applicable legislation, when a third party is required. This is told on the European Union’s 
website [30]. The European Commission publishes a list of approved notified bodies in 
a database called Nando [31].  
 
National authorities are responsible for the notified bodies. This is the same practice as 
with the earlier directive. In Finland, the authority is Fimea. The difference is that the 
MDR has a lot of new requirements for these bodies, especially as regards clinical qual-
ification. Therefore, granting the MDR authorization and later monitoring takes the bodies 
significantly more time than before. At the moment (situation in April 2020) there are no 
MDR-qualified notified bodies in Finland. For a couple of notified bodies, the approval 
process is ongoing.  
 
The manufacturer is recommended to follow whether the notified body they already have 
cooperation with is named on the basis of the new regulation, and whether its area of 
responsibility covers the company’s products. It is recommended to start cooperation 
with the notified body in planning the timing of the verification of the product portfolio 
immediately after the notified body is qualified, taking into account the availability of the 
notified body, need for additional information about the devices, and the transitional pro-
vision of the new regulation, because the MDR will soon become effective in full.  
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2.6 Summary of MDR 
The new regulation for medical devices became effective in May 2017. A transition period 
of three years was set for it, after which the current directive will expire. The Union’s goal 
for the new regulation is to remove the room for interpretation from the legislation, meet 
the challenges of developing technology, exclude problems that have occurred in use, 
improve safety and people’s health and support the functioning of the internal market 
while also maintaining the spirit of innovation. The patient safety of the devices will cer-
tainly improve because of the new regulation, but the goal of innovativeness is challeng-
ing, because the regulation’s requirements are strenuous, and the ability to understand  
and fulfil them, especially in start-up companies, will eliminate companies operating in 
the field and attempting to get there, Ben-Menahem and colleagues write in their scien-
tific article How the new European regulation on medical devices will affect innovation 
[32].  
 
The regulation contains the same requirements as the directive, but it will also bring 
additions and entirely new requirements. With the regulation, many software programs 
used with medical devices will become medical devices themselves. Picture 1, CE Mark-
ing Process, presents the regulation’s requirements that depend on the risk class of the 
device.   
 
For devices in a lower risk class (class I), a technical file which contains, for example, 
risk management, safety tests, clinical evaluation, post-market surveillance, and the dec-
laration of conformity (DoC) will be required. For devices in a higher risk class (Im, IIa, 
and IIb), in addition to the requirements above, also the participation of a notified body 
in the approval process, quality system (QMS), and a more detailed clinical evaluation/re-
search and reporting are required. A new requirement for all medical devices is the 
unique device identification (UDI) and the obligation to report several matters in the new 
information system, Eudamed. In the future, the large manufacturers of medical devices 
must have a person responsible for regulatory compliance employed by the company.  
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3 Materials and Methods 
3.1 Research Approach 
The purpose of this research was to draw up recommendations for the case company 
on how to comply with the requirements set forth in the new European law. The transition 
period of the regulation is approaching its end (26.5.2020), so the topic of this research 
is very current, and there is a lot of new information about it especially in the Internet. In 
addition, some of the company’s personnel had already familiarised themselves with the 
theme, for example by participating in MDR trainings, so there was existing expertise on 
the topic within the company. This made it easier to analyse the current state and to 
evaluate the recommendations.  
3.2 Research Design and Project Plan 
The problem with the case company is that it is not entirely known how the MDR should 
be implemented, because there are some things that have not been instructed yet. The 
goal of this research is to provide the missing recommendations that make the imple-
mentation easier. Several steps have been taken to create the recommendations (picture 
9 below).  
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Picture 9: Research Design 
 
First, information about the ongoing change and different research methods has been 
collected. There is plenty of new material on the MDR regulation, because the topic is 
very current. Chapter 2 (Medical Device Regulation) is about the existing information 
about obligations and the change. The selected research methods are described in chap-
ter 3 (Materials and Methods).  
 
The current state of the case company is analysed in chapter 4 (Current State Analysis), 
focusing especially on the parts of the legislation that will change the most, insofar as 
the actions for meeting them have not been carried out yet. After this, it was possible to 
outline recommendations regarding what the implementation of MDR still requires (chap-
ter 5: Recommendations for Implementation of MDR). So the result – the recommenda-
tions for meeting the requirements – would be as comprehensive as possible and would 
fulfil the needs accurately, it had to be evaluated before publishing. This was done by 
interviewing key people working at the company (chapter 6: Evaluation of Recommen-
dations). After this, it was still possible to update the recommendations, based on the 
findings from the interviews.  
31 
 
The last chapter (chapter 7: Conclusions and Discussion) includes the conclusions about 
the change and its influences on the company that sells medical devices in Europe. Fi-
nally, the recommendations are published as a Master’s Thesis both in the company and 
in Theseus, the shared database for theses from Finnish Universities of Applied Sci-
ences [33].  
3.3 Data Collection and Analysis 
The research method selected for this research was qualitative research and content 
analysis. The content was collected from twelve interviews (see the following chapters), 
so the result is in the qualitative category because of its volume. The content analysis 
was carried out according to the instructions given by Tuomi and Sarajärvi in their book 
Laadullinen tutkimus ja sisältöanalyysi [34]. First, the decision was made on which topics 
of the data were interesting, and others were separated and excluded from the research. 
The remaining data was divided into separate themes. Finally, a summary was written 
about the remaining data.  
 
The current state of the company (situation in February 2020) was analysed by inter-
viewing the company’s MDR specialist about what has already been done for the regu-
lation (chapter 4). The interview was conducted as a semi-structured personal interview. 
This means that parts of the MDR that may change compared to the expiring directive 
were collected in advance. The interview progressed part by part, and the questions for 
each part were the same – are changes needed when transitioning from the directive to 
the regulation, and if yes, has something been done already and are the actions already 
taken enough to fulfil the requirements set forth in the regulation.  
 
Based on the current state analysis interview, it was possible to identify the parts that 
still require actions to comply with the regulations. Recommendations about the neces-
sary actions, schedules, and resources were drawn up for them. The recommendations 
are based on the suggestions that came up during the interview and the facts discussed 
in the theory chapter (chapter 5, Recommendations for Implementation of MDR). The 
SMART criteria [35] were taken into account when creating the recommendations: The 
goal was to make them – if possible – Specific, Measurable, Achievable (who is respon-
sible for implementation), Relevant, and Time-bound.  
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In order to make the result of the research as reliable as possible and also consistent 
with the needs of the company, the result was evaluated by interviewing 12 key people 
working at the company. The interviewees were selected based on their long experience 
(several years) of activities complying with the directive, and the upcoming changes will 
directly affect their area of work. An additional criterion for the selection was an attempt 
to cover the company’s different lines of business as extensively as possible, to enhance 
the preparation for the information about the upcoming change throughout the whole 
company.   
 
The evaluation interviews for the recommendations were conducted as semi-structured 
personal or pair interviews. In their book about research interviews, Hirsjärvi and Hurme 
[36] use the term theme interview for semi-structured interviews. They describe that the 
questions in this interview type are the same for everybody, but the interviewees can 
answer in their own words; the answers are not limited by the given options, like in struc-
tured interview. A theme interview follows certain central themes, and there is no need 
to connect it exclusively to either qualitative or quantitative methods. This makes the 
interview more free from the researcher’s point of view, and gives more prominence to 
the voices, interpretations, and meanings of the interviewees.  
 
The theme interviews for evaluating the recommendations in this research were carried 
out by going through all recommendations one by one and by asking if the recommen-
dation is necessary and comprehensive, and if the interviewee has anything to add as 
regards the actions that are needed to meet the requirements set forth in the regulation.  
 
The interviewees were unanimous on the correctness and necessity of the recommen-
dations. There were also some good additional observations, so the recommendations 
were modified based on these, and a couple of new recommendations were added as 
well (chapter 6, Evaluation of Recommendations).  
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4 Current State Analysis 
 
4.1 Current State Analysis 
 
The case company has a long history in the European medical device market, because 
its first EC certificate dates back to 1995. However, the new regulation brings about new 
requirements and additions to old requirements. In order to start preparing for the 
changes, several people from different departments have acquainted themselves with 
the changes, some have participated in external trainings, and some changes have al-
ready been made in the company. Now there is a need for a current state analysis to 
evaluate what has already been done and what still needs to be done so that the com-
pany is ready to work in compliance with the MDR requirements.  
 
A specialist interview was chosen as the method by which to get information on the cur-
rent state. The interview was conducted and recorded on 15.1.2020 as a semi-structured 
personal interview, and its topic was the current state of the MDR requirements, with 
emphasis on quality. The interviewed specialist was a Process Development Manager, 
who works at the target company and whose education is Bachelor of Engineering in 
Information and Communications Technology. The specialist had learned about the 
MDR by trainings and self-education, and by attending working groups organized by 
Healthtech Finland. 
 
4.2 Specialist Interview  
 
Topic: The current state of the MDR requirements in the target company  
 
Time and place: 2020-01-15 in target company premises, in Helsinki  
 
Interviewee: Process Development Manager 
 
The interview was conducted by presenting the interviewee with the possible targets of 
changes title by title, selected from the regulation in advance. The questions for each 
were: Does the item require actions in order to meet the requirements in the regulation, 
and if it does, what is the status of these actions in the company. The items that the 
interviewee commented are presented below.  
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Distance sales  
 
According to current understanding, the company’s range does not include products or 
services that are delivered or used as intended in the article about distance sales.  
 
Use of harmonised standards  
 
The situation is open. The directive had a group of harmonised standards as an attach-
ment, and it included up to two or three hundred standards. Now this is completely open 
as regards the MDR, there have not been expressions of opinion on what is the group of 
standards that needs to be followed to fulfil the requirements set in the regulation. The 
common policy is to continue operations according to them, but they do not have a legal 
role in the world of MDR for the time being. The situation is interesting. For now, there 
are no other options to be seen but to continue using the current standards.  
 
General obligations for manufacturers  
 
The quality system obligation will apply to manufacturer, distributor, and some other func-
tions. The old way of working focused mostly on the manufacturing point of view, but 
now it expands to distribution and maintenance actions. The company should surely 
check what kind of guidelines it has for maintenance actions. The company trains the 
distributors, and they carry out maintenance in the field. He had also seen such policies 
and some companies interpret that the companies operating in distribution and mainte-
nance have to have a quality system. The company as a manufacturer has a quality 
system.  
 
The risk management system has been a part of the quality system. What will change is 
that the quality system should be built from risk management point of view; risks in dif-
ferent areas of operation should be assessed. The practical implementation is in accord-
ance with ISO 13485:2016. The standard operating procedure for product development 
risk management [37] has been renewed and complies with ISO 14971:2019. It is ready 
for MDR. 
 
Technical documents are a major challenge. The work instruction for the technical file 
has been made, and it takes a stand on different markets and their differences on the 
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global level. The basic structure is the structure of the MDR technical file. The work in-
struction describes the technical file at a conceptual level. Work is still in progress as 
regards the output/document of the case company, i.e. what corresponds to each section 
of the technical file. The challenge is that the company has different divisions that work 
in slightly different ways at the moment, and additional instructions are needed on what 
is the document template in the case company and what corresponds to each section of 
the technical file. A working group is now working on this as a part of the product process 
management project. The amount of work is tremendous. The schedule is uncertain.  
 
Customer documentation, such as labels and manuals: The guidelines will change as 
regards the software, he did not know about other changes. The MDR states explicitly 
the recommended location of the CE mark in the software. In the future, the CE mark 
must be in the first view the user sees. This change has already been taken into account 
in our upcoming software update.  
 
The Essential Requirements will change to General Safety and Performance Require-
ments, and he has created a new EU MDR Safety and Performance checklist for it. It 
collects new requirements (such as nano materials) and replaces the old ones. The list 
has been converted to checklist format, and it covers all elements and areas in sufficient 
detail. When the company develops something in the future, the list can be used to check 
that each area is covered in some way. It is a general-purpose checklist, suitable for all 
departments and products as it is. The checklist has not been released yet, but an an-
nouncement could be made to inform everyone about it.  
 
There is an existing working group in the Usability department. They are in charge of 
their entities, they are trained in MDR, and their operations have been updated. This is 
in a good shape considering MDR, efforts from the quality department have not been 
needed.  
 
UDI system requirements in EU will be new to the company.  
 
Person responsible for regulatory compliance  
 
This is a new requirement. Qualification requirements are defined, and the responsibili-
ties of this person are also described. The current quality director has announced avail-
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ability, but the job description has not been updated yet. There has been some discus-
sion in HealthTech Finland groups about the need for some kind of an insurance for the 
person in such role, personal-level protection.  
 
Declaration of Conformity  
 
There are new requirements in the content of the Declaration of Conformity, for example 
the UDI information and the intended use of the medical device have been added. The 
current Declaration of Conformity is based on the old standard, and the declarations sent 
recently to the notified body are already very close to the MDR requirement.  
 
Identification within the supply chain  
 
The roles will be defined in more detail (manufacturer, distributor, importer etc). The 
identification of the device in the supply chain will probably happen through the forth-
coming UDI system. Actors are obligated to identify and keep the information about the 
other actors to whom they have delivered the device or who have delivered the device 
to them for 10 years (15 years for implantable devices).  
 
UDI system/UDI database 
 
Seems to be still open/in open issue. According to the latest information, there will be an 
Italian UDI type, which is different from the FDA-UDI. There is a separate transition time 
for the European UDI, but this will naturally influence the way the company marks the 
products. The Commission has to provide information about the contents of the UDI. The 
products of the company are for the most part class IIa or IIb devices, and for them the 
UDI obligation will become effective on 26.5.2023. 
 
Registration of devices  
 
The notified body system will stay as it is. The use of possible national databases may 
be discontinued. The company will keep the same approval path based on the quality 
system. When the company modifies a product after May 2020, it has to be done in 
accordance with the MDR. After 2024 the delivery of a product is not allowed anymore if 
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it has not been registered in accordance with the MDR. He does not know about deci-
sions to leave some products without MDR registration.  
 
Notified bodies  
 
The company do not know when its current notified body will be MDR-designated. There-
fore, the company cannot yet apply for an approval in accordance with the MDR, even if 
that was otherwise possible. At the time of the interview, there are only 9 MDR-desig-
nated notified bodies in the European Union, and none of them is in Finland. According 
to the Commission’s notification from last autumn, the goal was to have about 20 notified 
bodies designated by the end of 2019, but clearly this schedule has not held.  
 
Classification of devices  
 
The company’s current products will probably stay in their current risk classes, maybe 
except for software. Some software that is currently not medical device may rise to class 
I, which means that a declaration is needed. These software products that are unclassi-
fied according to MDD and rise to class I because of MDR have to be classified and 
comply with the conformity requirements by May 26, 2020.  
 
Clinical evaluation and clinical investigations  
 
The Commission has emphasised in their communication that the notified bodies now 
really have to inspect the clinical investigations. A clinical evaluation is needed for each 
device, and at a minimum it means a comprehensive literature review. A large amount 
of work instructions [38] and document templates have been prepared. They have been 
released and are ready to be used. The instructions are ready for the MDR. Additional 
resource has also been hired, but it could be good to allocate more as regards updating 
the yearly report.  
 
For predicate devices the practice will change. The MDR says that it is possible to base 
on a product that has been released already, like with MDD, but a technical file is needed 
for the product to ensure sufficient similarity between the products. Because competitors 
probably will not give their technical files for us to use, this path is not possible.  
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The regular proactive follow-up after placing the clinical evaluation on the market and 
the report that is based on it, and depends on the product’s risk class, requires new skills. 
This procedure is related to the general follow-up after placing on the market.  
 
Post-Market Surveillance  
 
An essential change is that the PMS actions have to be proactive in the future, and in 
stead of passive collection of data they have to be based on preventive actions. The 
manufacturer is also required to set up a system for post-market surveillance. A good 
question is how this kind of action is proved. A way is to follow the incident reports in the 
archives of other countries to show that the company follows similar cases and considers 
if they could be like our own. However, this requires more detailed instructions at the 
company level. In the future, manufacturers have to provide a periodic device-specific 
safety review. In addition, a clinical follow-up report has to be saved to Eudamed, but in 
which format and when is not yet decided by the Commission.  
 
Reporting of serious incidents and field safety corrective actions  
 
A new requirement is a notification procedure through Eudamed, as soon as it is ready 
to be used and the Commission has given instructions on how to use it. The MDR lists 
requirements at a detailed level regarding the reporting of serious incidents and field 
safety corrective actions, but the actions themselves will probably stay as they are for 
the most part.  
 
Trends  
 
Statistical analysis is carried out and trends are followed already at the moment as a part 
of the quality system, for example in management reviews. Reports on trends are re-
quired to be given through Eudamed, but its adoption seems to be delayed from the 
Commission’s side. The related instructions have not been made yet.  
4.3 Summary of the current state 
The MDR came into effect in 2017, so the company has already had time to do several 
things to comply with the new regulations. Because there are no MDR-qualified notified 
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bodies in Finland at the moment and the Eudamed is not yet in use, it has not been 
possible for the company to do everything yet. Based on the specialist interview pre-
sented in section 4.2, the MDR readiness of the following areas can be deemed unnec-
essary or ready enough to be left out of the focus of this research, excluding the recom-
mendation to follow trends and the adoption of Eudamed, which applies to most of the 
following:   
• Distance sales  
• Use of harmonised standards  
• Quality system of the case company  
• Risk management system  
• Technical documents  
• General safety and performance requirements (GSPR) 
• Usability requirements  
• Notified bodies  
• Clinical evaluation and clinical investigations  
• Reporting of serious incidents and field safety corrective actions.  
 
The interview focusing on the current state revealed the following areas on which 
changes are needed but not yet done and will benefit from the recommendations pro-
vided by this research:  
• Notification/surveillance of the obligations of other economic operators than the 
manufacturer (e.g. possible quality system obligation and the identification of the 
product within the supply chain)  
• Person responsible for regulatory compliance  
• Declaration of Conformity 
• UDI 
• Classification of devices  
• Post-Market Surveillance 
• Trends.  
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5 Recommendations for Implementation of MDR 
 
Based on the current state analysis done in chapter 4, recommendations were created 
in order the company meets the requirements of the regulation. The recommendations 
are suggestions on how to update the current standard operating procedures in the qual-
ity system, or if they do not exist, how to create new ones to meet the needs of the 
company. Because it is not necessary to give instructions on all actions at an operating 
procedure level, some of the recommendations are requests to do some separate action. 
5.1 Person Responsible for Regulatory Compliance (PRRC) 
Recommendation: A PRRC is appointed by 26.5.2020 by company management  
 
One of the new requirements of the regulation is that the manufacturer has to have per-
manently (large companies) at least one person responsible for regulatory compliance 
in their organisation. If there are more than one person, the division of responsibilities 
has to be defined in writing. The person must be formally qualified for the task. The 
qualification is attained either by an appropriate university degree and one year of work 
experience, or by four years of work experience about regulations related to medical 
devices or quality management systems. In addition, it has been defined that the person 
must not be legally in weaker position within the organisation because he or she is per-
forming the duties. The requirements are described in more detail in chapter 2.2.1. 
 
The Finnish Enterpreneurs (in Finnish: Suomen Yrittäjät), classifies companies that em-
ploy at least 250 people as large companies [39]. Thus, the case company is a large 
company (it employs about 700 people in Helsinki), and it has to have at least one person 
responsible for regulatory compliance in the organization.  
 
The recommendation is to appoint a qualified person for the task or divide the responsi-
bility between several people, and make a written agreement about this by, for example, 
updating the job description. The appointment has to be done by the end of the transition 
time, and the person has to be registered in Eudamed as soon as it is possible.  
Taking into account the level of responsibility associated with the task, it is recommended 
that the person is a member of the Executive Board. Furthermore, it is recommended 
that the responsibility of the responsible person is limited in an agreement between the 
41 
 
company and the responsible person. In addition, the responsible person is advised to 
consider taking a personal liability insurance.  
5.2 Product Classification  
Recommendation: The conformity of software products that are sold for ready to use is 
ensured by 26.5.2020 by product managers  
 
The case company is responsible for class I, Im, IIa, and IIb devices and non-medical 
devices. As the specialist's interview indicated, the classifications will probably stay as 
they are, except the currently non-medical software. However, it is worthwhile to follow 
the Commission’s notifications, because it is possible that qualifications on the classifi-
cations are made at a later time. 
 
The MDR adds a new risk class classification rule (no 11) to the conformity assessment 
for software that is intended to provide information used in diagnostic or therapeutic de-
cision-making. In the future, such software will probably belong to risk class IIa with minor 
exceptions, and other software to class I.  
 
The recommendation is to evaluate the software that the case company is responsible 
for and that are sold after 26.5.2020. Because none of the current non-medical software 
is manufactured by the company, the recommendation is to send a letter to the manu-
facturers and ask them to confirm the risk class classification and be responsible for its 
requirements. The requirement for class I devices is the technical file and DoC. For class 
IIa devices it is required that the notified body and PMS are used. In addition, it may be 
necessary to update supplier contracts, taking into account MDR conformity.  
5.3 General Safety and Performance Requirements 
Recommendation: The existing instructions are released as soon as possible (on 
26.5.2020 the latest) by the process development manager  
 
42 
 
In order to meet the new MDR requirements, an EU MDF Safety and Performance check-
list has been created for the company. It collects new requirements together and re-
places the old ones. However, this checklist has not been released yet within the com-
pany (situation in February 2020), so the recommendation is to release it immediately. If 
that is done, any MDD compliant actions are not in jeopardy, but all upcoming changes 
would already be as compliant with the MDR as possible.  
5.4 Registration of Economic Operators 
Recommendation: The company is registered into Eudamed by the quality department 
 
The manufacturers of mass-produced devices have to register in Eudamed (when it is 
available) before placing the devices on the market. If the conformity assessment proce-
dure requires the participation of the notified body (devices in risk classes Im, IIa, and 
IIb), the manufacturer has to save the requested information in the electronic system 
before the registration request is presented to the notified body. After this, a competent 
authority acquires the manufacturer’s single registration number (SRN) and sends it to 
the manufacturer and the notified body. The manufacturer has to use the registration 
number when requesting for the conformity assessment from the notified body and to 
get into Eudamed to fulfil its other obligations. To conclude, it is recommended that the 
case company is registered in Eudamed as soon as possible.  
5.5 Unique Device Identifiers (UDI) 
Recommendation: The devices are registered in the UDI database by 26.11.2020 and 
introduced within the UDI schedule by the FDA-UDI responsible persons  
 
There is a new requirement in the regulation about the unique identification of devices. 
The purpose of the actions is to improve device traceability, make recalls easier, prevent 
forgeries and improve patient safety.  
 
A corresponding requirement is already in force and in use in the case company in the 
form of an American UDI (there is no official standard operating procedure). However, 
the European UDI is probably different from its counterpart in some respects, although 
they are both based on The International Guidance on a Unique Device Identification 
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(UDI) System for Medical Devices (2013) [21], created by the International Medical De-
vice Regulators Forum (IMDRF). Therefore, revising and updating the implementation to 
comply with the MDR is needed. The UDI requirement applies to all medical devices in 
Europe (except for custom-made devices). The UDI marking belongs to manufacturer's 
responsibilities, and the schedule varies between risk classes.  
 
Recommendations for meeting the UDI requirements are the following:  
• The company should be registered as a manufacturer in the Eudamed database 
(when available)  
• UDI-DI is recommended to be formed through the Commission-approved GS1 
AISBL issuing entity, because it is already used in the company  
• The devices should be registered into the UDI database (when available) by 26 
November 2021 (also software as a medical device)   
• Devices belonging to the risk classes IIa and IIb should be marked with the UDI 
identifiers by 26 May 2023  
• Devices belonging to the risk class I should be marked with the UDI identifiers by 
26 May 2025  
• UDI-DI has to be used at least in the following documents: User manuals, certif-
icates, DoC, and the technical file. 
  
Further information can be found in the European Union publication Unique Device Iden-
tification (UDI) System – FAQs [21] and in the instructions by GS1 Be ready for UDI in 
the EU! [20].  
5.6 Declaration of Conformity (DoC) 
Recommendation: The declarations of conformities should be updated to comply with 
the regulation in conjunction with the device-specific MDR approvals by the quality di-
rector  
 
The case company has created and updated declarations of conformities that comply 
with the expiring directive for all its medical devices, so there is already experience with 
the process. There are no instructions on the process, but because the responsibility will 
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probably stay with the current quality director (upcoming PRRC), there is no need for 
one-person-instruction.  
 
As stated in the current state interview (chapter 4), the DoC has already been slightly 
updated towards MDR as requested by the notified body. The current DoC mentions, for 
example, the name and address of the company, the official name of the product, notifi-
cation about MDD conformity, standards the product meets, the risk class of the product, 
declaration that the DoC is issued under the sole responsibility of the manufacturer, and 
the date and place of issue, name of the responsible person, title, signature, and infor-
mation about on behalf of or in the name of whom the person signs the declaration of 
conformity. As applicable, also the name and identification number of the notified body 
and a description of the conformity assessment procedure are given.  
 
The new additional DoC requirements to the information presented earlier are:  
• the registration number of the company (when Eudamed is available for use)  
• the unique UDI-DI identifier (when available)  
• the intended use of the device  
• updating the MDD compliance notification to MDR compliance  
• as applicable, the number of the certificate issued by the notified body. 
  
The recommendation is that these information should be updated to the current declara-
tions of conformities. 
5.7 Regulation’s Requirements for Economic Operators 
Recommendation: The distribution agreements should be updated by 26.5.2020 by the 
export department  
 
The regulation defines the manufacturer, authorised representative, importer, distribu-
tors and persons responsible for regulatory compliance as economic operators. The 
company's operations regarding manufacturer's responsibilities are already compliant, 
excluding the UDI markings (chapter 5.5) and PRRC (chapter 5.1). The company is lo-
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cated in the European Union area, in Helsinki, so an authorised representative and im-
porter for Europe are not needed. Taking these into account, the changes and updates 
for requirements for economics operators can be focused concerning only distributor re-
sponsibilities. 
 
It is recommended that the distribution agreements are checked and updated if needed 
concerning distributor’s obligations. If the agreements have not been updated recently, 
it may be necessary to inform the distributors about their responsibilities and schedule 
that the regulation sets out for them in written form. The distribution agreements or the 
notification should include the following points:  
• The distributor must check with a sampling method that the device has a CE mark 
and a MRD-DoC has been created for it, that the labels drawn up by the manu-
facturer and the instructions for use are supplied with the product, and the device 
has the UDI identifier. 
• The distributor has to make sure that the storage and shipping conditions meet 
the manufacturer’s requirements. 
• If the distributor suspects that the device is non-compliant, they cannot place the 
device on the market before compliance is achieved and the distributor has ful-
filled its notification obligation to the manufacturer, and in case of serious injury 
or suspected forgery, also to the competent authority. 
• Complaints and incident reports received by the distributor have to be forwarded 
to the manufacturer without delay. The distributor has to keep a register of com-
plaints, non-compliant products and product recalls, and withdrawals from mar-
ket. The distributor has to keep the manufacturer up to date about such monitor-
ing and provide the information if requested. 
• The distributors have to work in cooperation with authorities, which means that 
they have to provide the available information to demonstrate conformity, help 
with actions to remove the risks of devices placed on the market, and provide 
samples free of charge or the opportunity to access the device.  
• The requirements set forth in the regulation will become effective product by prod-
uct depending on when they are registered as MDR compliant by the manufac-
turer, but on 27.5.2024 at the latest. At the moment (situation in February 2020) 
none of the case company’s products are MDR compliant. From 26.5.2020 on-
wards, new products placed on the market or old products with significant 
changes have to be MDR compliant.   
5.8 Post-Market Surveillance (PMS) 
Recommendation: A new SOP is created as soon as possible (on 26.5.2020 the latest) 
by the process development manager  
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A new requirement in the regulation is that the manufacturer has to have a post-market 
surveillance (PMS) system. The quality system already in use in the company consists 
of standard operating procedures (SOP), so the PMS system requirement is fulfilled 
when an SOP is created for it and it is included in the quality system. At the moment 
(situation in February 2020) the case company does not have such an SOP.  
 
The recommendation is to create an SOP for post-market surveillance for the company. 
It has to be designed, set up, documented, developed, maintained, and updated actively 
and systematically. The collected data has to be analysed from the points of view of 
quality, safety, and performance. The actions have to cover the entire lifecycle of the 
product, and the provided data has to be sufficient for making conclusions to define, 
develop, and oversee corrective and preventive actions (CAPA). To help the practical 
work, it is recommended to use the relevant technical report published by the Interna-
tional Organization for Standardization (ISO): ISO/PRF TR 20416 Medical devices - 
Post-market surveillance for manufacturers [40].  
 
PMS is based on the plan on post-market surveillance (part of the technical file). The 
plan’s follow-up actions depend on the risk class of the device. The standard operating 
procedure has to include instructions for each risk class as follows:  
 
Risk class I devices and the PMS report  
 
Based on the PMS plan, the manufacturer has to draw up a PMS report for 
class I devices. The report summarises the results and the collected con-
clusions of the PMS data analysis together with the CAPA information. The 
report has to be updated as necessary and provided to the NB and the 
authorities if requested.  
 
Risk class IIa and IIb devices and a period safety update report (PSUR)  
 
For risk class IIa and IIb devices or device groups, the manufacturer has to 
draw up a PSUR (a part of the technical file) based on the PMS plan. The 
report summarises the results and the collected conclusions of the PMS 
data analysis together with the CAPA information. The class IIa report has 
to be updated as necessary and at least once every two years. The class 
47 
 
IIb report has to be updated at least yearly. The reports have to be provided 
to the NB and the authorities if requested.  
 
The collected information should be used, for example, in the following:  
• benefit-risk determination and the improvement of risk management  
• to improve design and manufacturing instructions, user manuals, and device la-
bels  
• to update the clinical assessment and safety and clinical performance summary  
• to define the need for preventive or corrective actions, or field safety corrective 
actions  
• to define the development potential of usability or the safety and performance of 
the device  
• to expand the PMS of other similar devices as applicable  
• to prevent and report of trends. 
 
Post-Market Clinical Follow-up (PMCF), which is also a post-market obligation, is in-
cluded in the existing instructions on clinical assessment at the case company (chapter 
4.2).  
5.9 Monitoring and reporting of trends 
Recommendation: A new SOP should be created as soon as possible by the process 
development manager  
 
The monitoring and reporting of trends is a new requirement that will become effective 
with the MDR. The company has followed the development of the field at some level, for 
example by monitoring competitors’ product ranges, by analysing the changing require-
ments of customer needs, and by reviewing the received customer feedback, but this 
monitoring has to be deepened and expanded due to the new regulation, and it has to 
be reported in a new way.  
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The new regulations regarding trends concern significant increases of unacceptable side 
effects. A significant increase is defined in relation to the foreseeable frequency or se-
verity of the side effect of the device in question during a particular period of time, as 
defined in technical documents and product information. The reporting has to be done 
through the electronic system (Eudamed). It is worth noting that this requirement does 
not apply to serious incidents (chapter 5.10).  
 
The recommendation is that in order to comply with the regulation, the company should 
create a new standard operating procedure for trend follow-up and reporting or include 
the requirement in an existing SOP (for example PMS, chapter 5.8) as a new chapter. 
The follow-up can be, for example, active monitoring of received customer feedback and 
existing incident databases, such as MAUDE/FDA [41] and Eudamed/EU (upcoming). 
To comply the requirement easier, it may be necessary to utilise statistical methods. The 
reporting has to be done through Eudamed, as soon as it is available.  
 
It would be good to mention in the SOP that the current actions have to be assessed 
based on the observations made in trend follow-up e.g. at the following levels:  
• benefit-risk determination and improvement of risk management  
• the improvement of design and manufacturing instructions, user manuals, and 
device labels  
• the improvement of the clinical assessment and safety and clinical performance 
summary  
• defining the need for preventive or corrective actions, or field safety corrective 
actions  
• defining the development potential of usability or safety and performance  
• expanding the PMS of other similar devices as applicable. 
5.10 Serious Incidents and Field Safety Corrective Actions (FSCA) 
Recommendation: SOPs of Vigilance and Creating and Delivering Technical Bulletins 
should be updated regarding Eudamed oblication by 26.5.2020 by the quality director  
 
The company’s procedure of reporting serious incidents is already compliant with the 
regulation. There are separate SOPs on creating incident reports, and they are analysed 
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according to the CAPA guidelines. However, the regulation adds a new requirement in 
the form of an electronic database, Eudamed. 
 
The recommendation on updating the SOPs Vigilance (in Finnish: Toimitetun laitteen 
aiheuttama vaaratilanne) [42] and Creating and Delivering Technical Bulletins (in Finn-
ish: Teknisen tiedotteiden laatiminen ja jakelu) [43] is needed because of these new ob-
ligations related to the reporting process. In the future, both serious incidents and field 
safety corrective actions have to be reported in Eudamed (when available).   
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6 Evaluation of Recommendations 
6.1 Interviews 
The goal of this thesis is to provide the case company with comprehensive and timely 
recommendations on how to comply with the requirements set forth in the MDR regula-
tion when the transition period ends in May 2020. Some changes required by the new 
regulation had already been done when the current state interview (chapter 4) was con-
ducted in January 2020. Based on that interview, recommendations were created (chap-
ter 5) to complement the actions that had already been taken and to meet the require-
ments that were not met yet. To make sure that the recommendations are of the correct 
kind and sufficient, an evaluation of the recommendations was carried out as internal 
interviews in the company.  
 
To evaluate the recommendations, a total of 12 people were interviewed from different 
areas of responsibility and departments. The interviewees were from the regulatory af-
fairs quality department (3 people), operative quality department (2 people), different di-
visions of product development (2+2 people), legal department (1 person), production (1 
person), and technical support of the customer service (1 person). One thing all inter-
viewees had in common was that they had a long work history at the case company or 
some other company that designs and manufactures medical devices. Therefore, they 
are familiar with the way of working that is compliant with the current directive as regards 
their own tasks. In addition, the recommendations will have an effect on their areas of 
responsibility. For some of the interviewees the topic was already partly familiar, for ex-
ample through an external course, but for others the contents of the regulation seemed 
to be new.  
 
The interviews were conducted as pair or personal interviews in the case company’s 
premises, and with remote workers as Microsoft Teams meetings during 26.2. – 
17.3.2020. They were recorded. The interviews followed the theme interview method in 
that the questions were based on the theme selected before the interview and they were 
the same for all, but the discussion was not limited except by the time reserved for the 
interview.   
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At the beginning the interviewees were told about the degree this thesis is part of. Next, 
the approval process was gone through at a general level (picture 1) with the interview-
ees, to help them gain an overall understanding and to make it easier to understand 
specific requirements. The interviews were valuable not only because the recommenda-
tions were evaluated, but also because during the interviews were presented a summary 
of the actions that had already been taken for the regulation and provided information 
about the upcoming actions that comply with the recommendations. The interviewees 
got the overall picture of the MDR requirements, and they commended its comprehen-
siveness.   
 
The recommendations were evaluated one by one, and the question about each was 
whether the recommendation is necessary and sufficient. At the end, the interviewees 
were asked to say if they know about something else to recommend related to the topic, 
and they were asked to arrange the recommendations in order of importance. Almost all 
interviewees said that deciding on the order of importance was difficult, because all rec-
ommendations are required by the law. It was only possible to find differences between 
them based on the schedule or the interviewee’s own area of responsibility.  
 
In the next chapter, the clarifications, changes, and additions that were made on the 
recommendations based on the interviews are described in more detail. The final rec-
ommendations, in the order of importance based on the interviews, are in chapter 6.3.  
6.2 Changes of Recommendations 
The purpose of the recommendation evaluation interviews was to analyse whether the 
recommendations are sufficient and timely to meet the requirements set forth in the up-
coming regulation. The recommendations were updated based on the findings from the 
interviews. Recommendation 5.3 (chapter 5) about General Safety and Performance Re-
quirement was removed, because the recommended actions had already been taken. 
Two new recommendations were added. The schedule (26.5.2020) for many of the rec-
ommendations was updated to ”by the end of the transition period”. Table 3 (below) pro-
vides a brief comparison of the differences between the final and original recommenda-
tions.  
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Table 3: Changes of recommendations  
 
Final recommendation  Change compared to earlier (chapter 5) 
Recommendation 1: A new SOP should be cre-
ated for Post-Market Surveillance by the end of 
the transition period of the regulation by the 
process development manager  
Added: Cyber and data security  
Recommendation 2: A Person Responsible for 
Regulatory Compliance (PRRC) should be named 
by the end of the transition period of the law by 
company management  
Added: In addition to the responsibilities, it 
would be good to agree on the authorisa-
tions in writing  
Recommendation 2: A Person Responsible for 
Regulatory Compliance (PRRC) should be named 
by the end of the transition period of the law by 
the company management  
Added: Insuring the person primarily by 
the company  
Recommendation 3: The conformity of software 
products sold to customers as ready to use 
should be ensured and the supplier contracts of 
OEM products should be updated by the end of 
the transition period by the product managers  
Added: Updating the supplier contracts of 
OEM products with MDR conformity and 
the case company’s new distributor re-
sponsibilities related to these  
Recommendation 4: The declarations of con-
formities (DoC) should be updated to comply 
with the requirements set forth in the regulation 
in conjunction with the device-specific MDR ap-
provals by who signs the declaration  
Added to the DoC content requirement 
list: ”all standards and requirements that 
the product fulfils…”  
Recommendation 4: The declarations of con-
formities (DoC) should be updated to comply 
with the requirements set forth in the regulation 
in conjunction with the device-specific MDR ap-
provals by who signs the declaration  
Changed responsible person: Quality di-
rector -> Person who signs the declara-
tions  
Recommendation 5: SOPs of Vigilance and Creat-
ing and Delivering Technical Bulletins  
should be updated regarding the Eudamed obli-
gation by the end of the transition period by the 
persons responsible for the SOPs   
Changed responsible person: Quality di-
rector -> Persons responsible for the SOPs  
Recommendation 6: The company is registered 
into Eudamed by the quality department.  
No changes  
Recommendation 7: The devices are registered 
in the UDI database by 26.11.2020 and intro-
duced within the UDI schedule by the FDA-UDI 
responsible persons   
No changes  
Recommendation 8: The distribution agree-
ments should be updated with the distributors’ 
new MDR responsibilities by the end of the tran-
sition period by the export department  
No changes  
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Recommendation 9: A new SOP should be cre-
ated for trend follow-up by the end of the transi-
tion period by the process development man-
ager 
No changes  
Recommendation 10: All SOPs (as applicable) 
should be updated as soon as possible by the 
persons responsible for them 
New recommendation  
Recommendation 11: The Medical Device sym-
bol should be added to the type labels and man-
uals by the end of the transition period by the 
product managers 
New recommendation  
6.3 Final Recommendation 
According to current knowledge, the new regulation for medical devices sold in Europe 
will become effective in full on 26.5.2020. However, it is possible that the schedule will 
change. On 25.3.2020, the European Commission released an announcement [44] say-
ing that because patient health and safety are their guiding principles, they propose that 
the implementation of the MDR regulation (2017/245) is postponed by a year. The Com-
mission’s goal is to submit their proposal about the postponement at the beginning of 
April, so that the parliament and the council can approve it by the end of May. A year of 
extra time would be warmly welcomed and needed by the Commission, the notified bod-
ies, and economic operators, considering both the MDR challenges and the current chal-
lenges caused by the coronavirus (COVID-19).  
 
In this thesis, recommendations have been created for the case company on how to 
meet the requirements of the upcoming regulation and continue manufacturing and sales 
in Europe. The recommendations cover the areas and activities for which the necessary 
changes had not been made yet in January 2020. The recommendations evaluated and 
deemed necessary by specialists and the new recommendations that came up in the 
interviews are listed below.  
 
Recommendation 1: A new SOP should be created for Post-Market Surveillance (PMS) 
by the end of the transition period of the regulation by the process development manager  
 
The recommendation is to create an SOP for post-market surveillance for the company, 
because it is a new requirement set forth in the regulation. It has to be designed, set up, 
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documented, developed, maintained, and updated actively and systematically. The col-
lected data has to be analysed from the points of view of quality, safety, and perfor-
mance. The procedure has to cover the entire lifecycle of the product, and the provided 
data has to be sufficient for drawing conclusions to define, develop, and oversee correc-
tive and preventive actions. The SOP has to contain separate instructions for each risk 
class as follows:  
• Risk class I devices: PMS plan and report (updated as necessary)  
• Risk class IIa devices/device groups: PMS plan and a Period Safety Update Report 
(PSUR) (updated every two years)  
• Risk class IIb devices/device groups: PMS plan and a Period Safety Update Report 
(PSUR) (updated yearly).  
 
To help creating the SOP, it is recommended to use the technical report published by 
the International Organization for Standardization (ISO): ISO/PRF TR 20416 Medical 
devices - Post-market surveillance for manufacturers [40]. An additional recommenda-
tion is to collect data related to cyber and data security, because the requirements and 
threats related to these increase all the time.  
 
Recommendation 2: A Person Responsible for Regulatory Compliance (PRRC) should 
be named by the end of the transition period of the law by the company management  
 
One of the new requirements of the regulation is that the manufacturer has to have per-
manently at least one person responsible for regulatory compliance in their organisation. 
The law stipulates that the person must not be legally in weaker position within the or-
ganisation because he or she performs these duties. The recommendation is to appoint 
a qualified person for the task or divide the responsibility between several qualified per-
sons. It is recommended to create a written agreement on the responsibilities and au-
thoritisations, for example by updating the job description. The naming has to be done 
by the end of the transition period of the regulation, and the person(s) have to be regis-
tered in Eudamed when it is available.  
 
Taking into account the level of responsibility associated with the task, it is recommend-
ed that the person is a member of the Executive Board. It is also recommended that the 
company arranges a liability insurance for the responsible person, but otherwise the re-
sponsible person is advised to consider taking a personal insurance.  
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Recommendation 3: The conformity of software products sold to customers as ready to 
use should be ensured and the supplier contracts of OEM products should be updated 
by the end of the transition period by the product managers  
 
The MDR adds a new risk class classification rule (no 11) to the conformity assessment 
for software. The recommendation is to evaluate the software that the case company is 
responsible for and that is sold after the transition period ends. Because none of the sold 
currently non-medical software is manufactured by the company, the recommendation 
is to send a letter to the manufacturers and ask them to confirm the risk class classifica-
tion and be responsible for its requirements.   
 
The company also has other products (currently medical devices) that are bought ready 
and sold forward, either under the company’s own or the original manufacturer’s respon-
sibility. They are called original equipment manufacturer products (OEM). Updating the 
supplier contracts for both the software mentioned above and the other OEM products 
taking into account MDR conformity would be necessary. Another noteworthy thing are 
new distributor responsibilities (recommendation 8 below), which concern some of the 
OEM products in the case company.  
 
Recommendation 4: The declarations of conformities (DoC) should be updated to com-
ply with the requirements set forth in the regulation in conjunction with the device-specific 
MDR approvals by who signs the declarations  
 
In order to comply with the requirement set forth in the regulation, the recommendation 
is that the information below is updated to the current declarations of conformities: 
• the registration number of the company (when Eudamed is available for use)   
• the unique UDI-DI identifier (when available)  
• the intended use of the device  
• updating the MDD compliance notification to MDR compliance  
• as applicable, the number of the certificate issued by the notified body  
• all standards and requirements that the product fulfils, because there can be only 
one DoC for each product.  
 
Recommendation 5: SOPs of Vigilance and Creating and Delivering Technical Bulletins  
should be updated regarding the Eudamed obligation by the end of the transition period 
by the persons responsible for the SOPs  
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In order to meet the new reporting obligations for Serious Incidents ja Field Safety Cor-
rective Actions (FSCA), the recommendation is to update the SOPs Vigilance (in Finnish: 
Toimitetun laitteen aiheuttama vaaratilanne) [42] and Creating and Delivering Technical 
Bulletins (in Finnish: Teknisen tiedotteiden laatiminen ja jakelu) [43] regarding the Eu-
damed reporting obligation.  
 
Recommendation 6: The company is registered into Eudamed by the quality department 
 
The manufacturers of mass-produced devices have to register in Eudamed (when it is 
available) before placing the devices on the market. If the conformity assessment proce-
dure requires the participation of the notified body (devices in risk classes Im, IIa, and 
IIb), the manufacturer has to save the required information in the electronic system be-
fore the registration request is presented to the notified body. After this, a competent 
authority acquires the manufacturer’s single registration number (SRN) and sends it to 
the manufacturer and the notified body. The manufacturer has to use the registration 
number when requesting for the conformity assessment from the notified body and to 
get into Eudamed to fulfil its other obligations. So, the recommendation is that the case 
company is registered in Eudamed as soon as possible.   
 
Recommendation 7: The devices are registered in the UDI database by 26.11.2020 and 
introduced within the UDI schedule by the FDA-UDI responsible persons   
 
There is a new requirement in the regulation about the unique identification of devices. 
Recommendations for meeting the UDI requirements are the following:  
• The company should be registered as a manufacturer in the Eudamed database 
(when available)  
• UDI-DI (chapter 2.2.9, picture 6) is recommended to be formed through the Commis-
sion-approved GS1 AISBL issuing entity, because the company already uses it  
• The devices should be registered into the UDI database (if available) by 26 Novem-
ber 2021 (also software as a medical device)   
• Devices belonging to the risk classes IIa and IIb should be marked with the UDI iden-
tifiers by 26 May 2023  
• Devices belonging to the risk class I should be marked with the UDI identifiers by 26 
May 2025  
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• UDI-DI has to be used at least in the following documents: User manuals, certificates, 
DoC, and the technical file  
 
Further information can be found in the European Union publication Unique Device Iden-
tification (UDI) System – FAQs [21] and in the instructions by GS1 Be ready for UDI in 
the EU! [20].  
 
Recommendation 8: The distribution agreements should be updated with the distributors’ 
new MDR responsibilities by the end of the transition period by the export department  
 
The regulation defines new responsibilities for distributors. So that the responsibilities 
between the case company and its distributors are clear, it is recommended that the 
distribution agreements are updated with the distributors’ new MDR responsibilities. In 
the future, the distributor responsibilities include the following, for example:  
• The distributor must ensure with a sampling method that the device has a CE mark 
and a MRD-DoC has been created for it, that the labels drawn up by the manufacturer 
and the instructions for use are supplied with the product, and the device has the UDI 
identifier 
• The distributor has to make sure that the storage and shipping conditions meet the 
manufacturer’s requirements  
• If the distributor suspects that the device is non-compliant, they cannot place the 
device on the market before compliance is achieved and the distributor has fulfilled 
its notification obligation to the manufacturer, and in case of serious injury or sus-
pected forgery, also to the competent authority  
• Complaints and incident reports received by the distributor have to be forwarded to 
the manufacturer without delay. The distributor has to keep a register of complaints, 
non-compliant products and product recalls, and withdrawals from market. The dis-
tributor has to keep the manufacturer up to date about such monitoring and provide 
the information if requested.  
• The distributors have to work in cooperation with authorities, which means that they 
have to provide the available information to demonstrate conformity, help with actions 
to remove the risks of devices placed on the market, and provide samples free of 
charge or the opportunity to access the device.  
 
Recommendation 9: A new SOP should be created for trend follow-up by the end of the 
transition period by the process development manager  
 
The new regulations regarding trends concern significant increases of unacceptable side  
effects. A significant increase is defined in relation to the foreseeable frequency or se-
verity of the side effect of the device in question during a particular period of time, as 
defined in technical documents and product information.  
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The recommendation is that in order to comply with the regulation, the company should 
create a new SOP for trend follow-up and reporting or include the requirement in an 
existing SOP (for example PMS, recommendation 1 above) as a new chapter. The fol-
low-up can be, for example, active monitoring of received customer feedback and exist-
ing incident databases (MAUDE/FDA active [41], Eudamed/EU upcoming). To comply 
the requirement easier, it may be necessary to utilise statistical methods. The reporting 
has to be done through Eudamed, as soon as it is available.  
 
Recommendation 10: All SOPs (as applicable) should be updated as soon as possible 
by the persons responsible for them  
 
The recommendation is to evaluate the current SOPs, and if necessary, make the fol-
lowing changes to them:  
• Valvira is mentioned in some of the company’s current standard operating proce-
dures. Because the responsibility for medical devices was transferred from Valvira to 
Fimea [45], the recommendation is to update the SOPs by removing Valvira and 
replacing it with the competent authority.  
• In the current SOPs, there are references to the current directive. Because over the 
next few years the company will have both MDD and MDR compliant devices, the 
SOPs should be updated to include references to both of them.  
 
Recommendation 11: The Medical Device symbol should be added to the type labels 
and manuals by the end of the transition period by the product managers  
 
A new requirement in the regulation is that the manufacturer has to mark its products 
with a Medical Device symbol. A sample symbol was found on the MedTech Europe 
website (in the picture 10 below).  
 
  
Picture 10: Medical Device Symbol [46]  
 
The recommendation is to monitor the harmonization of the standard ISO 15223-1 Med-
ical devices — Symbols to be used with medical device labels, labelling and information 
to be supplied — Part 1: General requirements [47] and take it into account when select-
ing the symbol. This makes it possible to use the same symbol not only in Europe but in 
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almost all countries. The symbol has to be added to the type labels and manuals of 
medical devices by the end of the transition period.  
 
Common recommendations 
 
As different specialists mentioned in the interviews, by acting on these recommendations 
the company complies with the requirements set forth in the regulation. However, it is 
still recommended that the company actively monitors the notifications issued by the 
Union, because the requirements may still be supplemented, the end of the transition 
period may change, and currently open issues (such as harmonized standards, MDR 
approvals of notified bodies, and the availability of Eudamed) may be solved.  
  
60 
 
7 Conclusion and Discussion 
 
The manufacturers of medical devices faced a big challenge when the Union replaced 
the MD directive that had been in use for about three decades with the new MD regula-
tion that became effective in 2017. The Union’s goal was to remove the room for inter-
pretation from the legislation, meet the challenges of developing technology, exclude 
problems that had occurred in use, improve safety and people’s health and support the  
functioning of the internal market while also maintaining the spirit of innovation. Accord-
ing to current knowledge, the transition period of the regulation probably ends in May 
2021, so the topic is very current.  
 
The case company for which this thesis was made has operated in the European market 
for several decades, designing and manufacturing medical devices. Because Europe is 
the main market area for the company, it is crucial that the company is able to meet the 
challenge brought by the MDR and fulfil its requirements, which are prerequisites for 
continuing operations in Europe.  
 
The theory section of this thesis provides a comprehensive information package on the 
new regulation. The MDR requirements affect different stages of the approval process, 
and therefore the theory section describes, for example, the increased requirements of 
quality management, risk management, and incident report system. New requirements 
are described in more detail, and they have their own sub-chapters (below).   
 
There has long been a requirement in the pharmaceutical industry regarding a person 
responsible for pharmacovigilance. Now a similar requirement is introduced for medical 
devices: person responsible for regulatory compliance. The qualification requirements 
and responsibilities of such person, for example, are described in the theory section.  
 
The requirement for unique device identification (UDI) will become effective also in the 
European market area, like it already is in the US. With the help of UDI, it is possible to 
guarantee the traceability of medical devices and ensure that they comply with the pa-
tient safety requirements of the European Union. The goal is to prevent incidents such 
as the breast implant scandal from happening again.  
 
In order to further improve patient safety, the regulation brings a requirement for post-
market surveillance system. In the future, information has to be collected from both the 
61 
 
company’s own (PMS) and other companies’ (Trends) devices. After analysis, actions 
are required, for example, on informing patients and risk management updates.  
 
The new European electronic information system (Eudamed) will be opened in 2022, 
according to current knowledge. The information system will collect information about, 
for example, device approvals, UDIs, notified bodies, economic operators, clinical inves-
tigations and incident reports. Because the system is so comprehensive, there will be 
much more information than before, but for manufacturers, for example, this means in-
creased documentation obligation.  
 
In the practical section of the Master’s thesis, the current state of the company was an-
alysed, and based on that, recommendations were drawn up on how to meet the new 
requirements of the regulation. The resulting recommendations on fulfilling the require-
ments were created to make the challenge easier for the case company. The recommen-
dations were created specifically for those parts of the regulation for which the actions 
were still incomplete or not taken in January 2020. To make the recommendations as 
comprehensive and well-targeted as possible, they were evaluated with the help of spe-
cialists. The company’s specialists believe that by meeting these updated recommenda-
tions the case company will comply with the requirements set forth in the regulation. In 
addition, one of the specialists suggested that the recommendations created in this the-
sis could be used as the quality targets for the next five years at the case company.  
 
The actions taken based on the final recommendations will eventually be audited by a 
notified body. This will provide valuable information about their interpretation, and the 
actions can be updated to comply even better with their and the authorities’ require-
ments.  
 
Considering that the previous directive was effective for decades, it is to be expected 
that also the new MDR will be effective for a long time. Therefore, with the help of these 
recommendations the case company can continue and further expand operations in Eu-
rope now and during the coming decades.  
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